How does CHOSA's PB Ratio compare to its peers?

CHOSA is expensive based on its Price-To-Book Ratio (2x) compared to the peer average (1.7x).

How does CHOSA's PB Ratio compare vs other companies in the SE Biotechs Industry?

CHOSA is good value based on its Price-To-Book Ratio (2x) compared to the Swedish Biotechs industry average (2x).

What is CHOSA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CHOSA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of CHOSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHOSA (SEK0.53) is trading below our estimate of [[fair value]] (SEK130.85)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Chosa Oncology NGM:CHOSA Stock Report

Last Price

SEK 0.53

Market Cap

SEK 34.4m

7D

0%

1Y

-59.2%

Updated

30 Apr, 2024

Data

Company Financials

Chosa Oncology AB

NGM:CHOSA Stock Report

Market Cap: SEK 34.4m

CHOSA Stock Overview

Develops oncology drugs for the treatment of cancer. More details

CHOSA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 99.6% below our estimate of its fair value

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (SEK34M)

Makes less than USD$1m in revenue (SEK0)

Less than 3 years of financial data is available

My Notes

Capture your thoughts, links and company narrative

Chosa Oncology AB Competitors

Respiratorius

NGM:RESP

SEK 31.9m

CombiGene

OM:COMBI

SEK 46.3m

Lipigon Pharmaceuticals

OM:LPGO

SEK 20.7m

Modus Therapeutics Holding

OM:MODTX

SEK 48.0m

Price History & Performance

Summary of share price highs, lows and changes for Chosa Oncology
Historical stock prices
Current Share Price	SEK 0.53
52 Week High	SEK 2.25
52 Week Low	SEK 0.30
Beta	0
1 Month Change	0%
3 Month Change	51.43%
1 Year Change	-59.23%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-62.30%

Recent News & Updates

Recent updates

Shareholder Returns

	CHOSA	SE Biotechs	SE Market
7D	0%	-1.6%	0.3%
1Y	-59.2%	19.8%	13.5%

Return vs Industry: CHOSA underperformed the Swedish Biotechs industry which returned -2.4% over the past year.

Return vs Market: CHOSA underperformed the Swedish Market which returned 9.4% over the past year.

Price Volatility

Is CHOSA's price volatile compared to industry and market?
CHOSA volatility
CHOSA Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	12.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: CHOSA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine CHOSA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2022	n/a	Peter Jensen	www.chosaoncology.com

Chosa Oncology AB develops oncology drugs for the treatment of cancer. The company was formerly known as Chosa ApS. Chosa Oncology AB incorporated in 2022 and is based in Lund, Sweden.

Chosa Oncology AB Fundamentals Summary

How do Chosa Oncology's earnings and revenue compare to its market cap?
CHOSA fundamental statistics
Market cap	SEK 34.38m
Earnings (TTM)	-SEK 23.94m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Is CHOSA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CHOSA income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 23.94m
Earnings	-SEK 23.94m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 10, 2024

Earnings per share (EPS)	-0.37
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CHOSA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/30 06:39
End of Day Share Price	2024/02/01 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chosa Oncology AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.